Enterprise Value

-10.27M

Cash

27.17M

Avg Qtr Burn

-8.428M

Short % of Float

0.41%

Insider Ownership

11.80%

Institutional Own.

20.15%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details
Cancer, Melanoma, Head and neck squamous cell carcinoma

Phase 2

Data readout

GB1211 (oral galectin-3 inhibitor) Details
Non-alcoholic steatohepatitis , Cirrhosis

Phase 2

Update

GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details
Non-small cell lung carcinoma, Cancer, Fibrosis

Phase 2a

Interim update

Phase 2a

Update

GB0139 (inhaled galectin-3 inhibitor) Details
Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis

Failed

Discontinued